
Summit Therapeutics reports 25% lower death risk in biliary-cancer trial
Ivonescimab plus chemotherapy extended median survival to 14.9 months in a China-only study, with a separate U.S. trial planned.

Three new holes support mineralisation to at least 300 metres depth, with more than 32 holes still awaiting complete assays.

Ivonescimab plus chemotherapy extended median survival to 14.9 months in a China-only study, with a separate U.S. trial planned.

Pumitamig plus docetaxel showed early activity after immunotherapy and chemotherapy, but the Phase 2 study had no control arm.
Severe or worse treatment-related adverse events affected 72.1 per cent across expansion cohorts; FDA talks are planned for 2027.
The single-arm analysis includes unconfirmed responses and supports two enrolling Phase 3 trials; median response duration was not disclosed.

The uncontrolled first-line analyses support continued development, with randomized SUNRAY-01 results expected in the first half of 2027.

Directors retain discretion over the ratio for common and exchangeable shares, with no effective date set in the voting disclosure.

Five of 13 patients reached immunologic remission at 12 weeks, while higher-dose cohorts and longer follow-up will guide development.

A US$1.2 billion agreement spans 2026 to 2030, while a one-time tariff refund lifted the September quarter’s reported earnings.
USW Local 7619 represents about 1,200 workers at the B.C. copper operation, whose production loss has not been quantified.
The California services acquisition would close in two stages, with cash, a seller note and an earnout subject to separate utility approvals.
Rigs are secured for approved drilling at Aberfoyle and Great Pyramid, while separate tailings work awaits regulatory approval.
The delayed draw facility starts with US$171 million borrowed and a 180-day maturity, with an extension tied to supply agreements and lender consent.
The interval also returned 0.83 per cent antimony, but true widths remain unknown after the completed 14-hole campaign.
A 131-patient registry analysis found higher graft risk, while a separate randomized trial reported 49% fewer kidney biopsies.
A 1,859-patient pivotal trial will compare the resorbable implant with Xience, with primary completion estimated for June 2029.
Gold, silver, uranium, lithium, copper and rare earths: the producers, the developers and the projects behind them.
View all
Fortum's jointly owned disposal company must complete commissioning and pass a STUK inspection before operations can begin.
Medical and pharmaceutical developments, psychedelics, and the research and safety questions around them.
View all
Genmab will conduct the Phase 1/2 study, while Incyte will co-fund it and supply its KRAS G12D inhibitor; a start date was not disclosed.
Technology, computing, crypto and cannabis, and the listed companies moving in them.
View all
Google will fund flexible household and business resources in PJM, but the companies disclose no price or delivery schedule.
Proprietary bitcoin holdings remained at zero as of Oct. 23, while the update omitted sale prices and cash proceeds.
Uranium, lithium, oil and gas, hydrogen and the grid: the fuels and the companies behind them.
View all
The National Wealth Fund is providing £12.2 million, with admission targeted for Nov. 12 subject to shareholder approval.

An initial study is estimated at six months; NANO disclosed no retainer amount, fabrication price or component delivery date.

Construction is underway on a commercial LEU+ factory, with listed owners Cameco and Brookfield Renewable exposed through their Westinghouse interests.
Licensed producers, retail, policy, and the psychedelics companies moving through the clinic.
View all
The capsules are intended for three programs, including a Canadian Phase 3 PTSD trial of up to 100 people expected to begin in 2027.

The province estimates illegal retailers take 30 per cent of cannabis sales and proposes inspection, seizure and penalty powers for the AGCO.

The bid offers US$1 in cash plus 0.4013 Curaleaf shares for each Aurora share, with a Dec. 4 tender deadline.

Cash earnouts tied to 2026 and 2027 earnings add to the base price for a grower supplying nearly all 69 shops in the Dutch pilot.